CRISPR Therapeutics AG (NASDAQ:CRSP) Given Average Recommendation of “Hold” by Brokerages

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have been assigned an average recommendation of “Hold” from the nineteen analysts that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $74.94.

Several analysts have recently weighed in on CRSP shares. Rodman & Renshaw started coverage on shares of CRISPR Therapeutics in a research note on Friday, August 2nd. They set a “buy” rating and a $90.00 price target for the company. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research note on Thursday. Royal Bank of Canada reissued a “sector perform” rating and issued a $53.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday. Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a research note on Thursday, August 8th. Finally, Truist Financial reduced their price objective on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, August 12th.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP opened at $51.88 on Friday. The company has a market cap of $4.41 billion, a P/E ratio of -16.06 and a beta of 1.67. CRISPR Therapeutics has a 1 year low of $43.42 and a 1 year high of $91.10. The firm has a 50-day simple moving average of $47.38 and a two-hundred day simple moving average of $52.24.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.42) by $0.41. The firm had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. During the same period in the previous year, the business earned ($1.41) EPS. As a group, equities research analysts expect that CRISPR Therapeutics will post -5.57 EPS for the current year.

Insider Activity

In related news, General Counsel James R. Kasinger sold 1,089 shares of the company’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the transaction, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, General Counsel James R. Kasinger sold 1,089 shares of the company’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the sale, the general counsel now owns 62,597 shares of the company’s stock, valued at approximately $2,896,989.16. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Samarth Kulkarni sold 4,293 shares of the stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the sale, the chief executive officer now directly owns 226,540 shares of the company’s stock, valued at approximately $10,484,271.20. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.10% of the company’s stock.

Institutional Trading of CRISPR Therapeutics

Hedge funds have recently made changes to their positions in the company. Global Trust Asset Management LLC grew its stake in shares of CRISPR Therapeutics by 150.0% in the 2nd quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock valued at $27,000 after buying an additional 300 shares during the period. Larson Financial Group LLC grew its stake in shares of CRISPR Therapeutics by 95.5% in the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after buying an additional 276 shares during the period. GPS Wealth Strategies Group LLC grew its stake in shares of CRISPR Therapeutics by 99.7% in the 2nd quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock valued at $33,000 after buying an additional 307 shares during the period. Itau Unibanco Holding S.A. purchased a new position in shares of CRISPR Therapeutics during the 2nd quarter worth approximately $35,000. Finally, Denver PWM LLC purchased a new position in shares of CRISPR Therapeutics during the 2nd quarter worth approximately $45,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.